1. www.ipha.ie Mr David Gallagher, President The Value of Scientific and Medical Innovation

2. www.ipha.ie Medical innovation in Ireland delivers benefits to patients as well to Ireland’s economy In 2010, Ireland invested 1.79% of Gross Domestic Product (GDP) in Research and Development (R&D) activities, which falls short of the European (EU27) average of 2 % and is significantly less than the European leader, Finland (3.87%) 1 However, Ireland is the largest net exporter of medicines in the world 3 Pharmaceuticals, along with chemicals and medical products, account for 50% of Irish exports, as well as spurring innovation through manufacturing and R&D-based activities These facets are all critical to Ireland’s drive toward a 'Smart Economy' while also contributing significantly to the country’s health and well-being 1 Eurostat (2011), 2 WHO (2006), 3 IPHA (2011) 2

3. www.ipha.ie Employment figures from the Central Statistics Office Ireland show that activities related to the pharmaceutical and life sciences sectors as shown in the graphic opposite (professional, scientific, and technical activities) have fared well through the economic downturn 1 The pharmaceutical industry directly employed 25 300 people as well as over 24 500 people in related sectors 2 Ireland was ranked first for skilled labour and second for the productivity of its workforce in the Institute for Management Development (IMD) World Competitiveness Yearbook* 2011 3 The pharmaceutical sector has in the past been more resilient than other sectors during economically challenging times, translating into increased job retention The pharmaceutical sector is a major employer and helps drive demand for higher education Ireland Employment Data 1 1 CSO (2011), 2 IBEC (2011), 3 IMD (2011), 4 gradireland.com (2011) Survey results by GradIreland.com show that the best paid graduate jobs in 2010 were in engineering & manufacturing 4 * The IMD World Competitiveness Yearbook is the leading annual report on the competitiveness of nations and benchmarks the performance of 59 countries based on 331 criteria measuring different facets of competitiveness.

4. www.ipha.ie Innovative medicines have contributed to an increase in life expectancy 40%-59% of the total increase in life expectancy across 52 countries, including Ireland, is attributable to innovative medicine launches. Life expectancy is continuing to increase as a result of progress in the treatment and prevention of cardiovascular disease and cancer 1 1 Lichtenberg (2005) 40%-59% of the increase in life expectancy is due to innovative medicine 1

5. www.ipha.ie Impact of innovation within therapeutic areas

6. www.ipha.ie Heart Disease  Pharmaceutical intervention plays a major role in the decline in coronary heart disease mortality in Ireland  Mortality from acute myocardial infarction (AMI) in Ireland decreased by 45% between 1997 and 2009 2 Diabetes  The incidence of diabetes in Ireland is increasing due to lifestyle choices and an ageing population  In 2005, it was estimated that 4.7% of the Irish population suffered from diabetes, 85- 90% of whom have type 2 diabetes (T2D) 3  The WHO estimated that in 2000 there were 86 000 cases of diabetes in Ireland. This figure is expected to double to 157 000 by 2030 5 Diseases of the circulatory system 1 Trends in age standardised death rates (Ireland data) 1 DOHC (2011), 2 Eurostat (2010), 3 INIsPHO (2005), 4 IPH (2010), 5 WHO (2011) Diabetes prevalence will continue to rise in Ireland 4

7. www.ipha.ie Cancer  Cancer mortality in Ireland is decreasing despite its increasing incidence  The most prevalent invasive cancers are prostate cancer in males and breast cancer in females, accounting for 30% and 32% of cancers respectively 2  Personalised medicine specifically tailors medical care to that individual’s need based on their unique genetic profile to produce greater efficacy with fewer side effects and potentially reduce costs  Oncology is the therapeutic area with the highest number of personalised medicines on the market and in the pipeline  Other areas of significant focus for personalised medicine include cardiovascular, central nervous system, and immunologic therapies. Between 2006 and 2010, pharma company investment in personalised medicine research increased by a mean of 75%, with an additional increase of 53% predicted by 2015 3 1 DOHC (2008), 3 NCRI (2011), 3 MPI (2011) Trends in age standardised all-cancer mortality rates 1974-2007 1

8. www.ipha.ie The impact of innovations in medicine can be seen across all therapeutic areas Therapeutic AreaImpact and Benefits Heart diseaseIncreased survival; treatments contributing to both the prevention and management of the disease DiabetesDelayed onset of complications; improved disease management and patient outcomes CancerReduction in mortality despite increase in incidence; evolution of personalised medicine offers improved efficacy Infectious diseasesTreatment and prevention of diseases resulting in decreased incidence of several more common diseases Rheumatoid arthritisInhibition of disease progression; reduced morbidity Orphan diseasesEnhanced survival; addressing unmet need of small patient populations Mental healthNewer medications offer fewer unwanted side effects and reduced rates of patients residing in psychiatric units

9. www.ipha.ie Innovative medicines and their importance for Ireland

10. www.ipha.ie Pharmaceutical innovation provides many patient benefits and is having a significant impact on public health in Ireland Pharmaceutical innovation Prevention of illness Inhibition and reversal of disease-related damage Reduced disease progression and disease- related events Increased survival Improved public health and increased life expectancy Social benefits and improved quality of life Reduced adverse events Increased therapeutic options Continued pharmaceutical innovation is vital for the continued improvement of public health

11. www.ipha.ie However, access to innovative therapies is not always optimal, reducing the benefits associated with innovation 1,2 EFPIA (2009) The level of uptake of novel therapies and the time period over which drugs become available to patients are important factors in achieving the benefits of innovation Availability: out of 84 agents that received EU market authorisation between 2007 and 2009, 64% (54) were made available to patients in Ireland 1 Access: in Ireland there is an average of 157 days between approval and market access in 2007-9, though this has become substantially more difficult recently, increasing by over 50% since 2006-8 (101 days) 1 Increasing number of innovative medicines currently not being reimbursed

12. www.ipha.ie The Irish government has developed a framework aimed at building Ireland’s Smart Economy Innovation is a principle ingredient in building a smart economy along with solid enterprise Four types of capital must operate in balance with each other as the foundation of innovation – human, environmental, social, and physical 1 Innovation is the fundamental component of a smart economy through ideas that are transformed into value-generating goods and services A key action area in the government’s Smart Growth Action Plan is to build the “ideas” economy to establish Ireland as the Innovation Island. One of the forces behind this is the export sector, with activities ranging from R&D to manufacturing 1 Future of Innovation “...Ireland must move up the value chain and assert itself not only as an open enterprise economy with a positive environment for FDI [foreign direct investment], but also as an open entrepreneurial economy with significant comparative advantages.” 1 www.taoiseach.gov.ie

13. www.ipha.ie Action Plan For Jobs Department of Health: “The Plan recognises the need for genuine collaboration between lifesciences firms and the healthcare system “to deliver economic growth, improved patient outcomes and lower healthcare services costs”. Quality health services, a vibrant health research system and economic prosperity are inextricably linked. Science technology and innovation all play an important role in realising improved health outcomes for the population (including the planning for, and delivery of, health systems and services) and more broadly for meeting major societal challenges.”